top of page

Taking a deep dive into atopic dermatitis with the CEO of Apogee Therapeutics

Michael Henderson describes the rationale behind Apogee's IL13 program and how it has been designed to have a longer half-life than competitors Regeneron/Sanofi and Eli Lilly.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page